Novartis AG vs Rent the Runway Inc — how do they compare? Novartis AG trades at $153.02 (market cap $295.37B), while Rent the Runway Inc trades at $3.62 (market cap $122.65M). The key difference: Novartis AG is far larger — about 2408.2× Rent the Runway Inc's market cap, and Novartis AG pays a 3.07% dividend while Rent the Runway Inc pays none. Which is the better fit depends on your goals.
| NVS | RENT | |
|---|---|---|
Market Cap | $295.37B | $122.65M |
Sector | Health | Consumer Cyclical |
52-Week High | $168.62 | $9.39 |
52-Week Low | $119.31 | $3.01 |
Enterprise Value | $336.69B | $282.75M |
Dividend Yield | 3.07% | — |
Signals from Pluang's Aura AI — not financial advice
Novartis AG (NVS) trades at $156.79, up 0.29% today, with a bullish technical signal from moving averages and recent Q2 2026 earnings beating estimates. Strong profitability is evident with a 74.74% gross margin and 22.5% net margin, while revenue grew to $56.67B in 2025. The stock faces resistance near $157, with support at $156.
The outlook is positive due to robust drug pipeline progress and reaffirmed 2026 guidance, though risks include generic competition for Entresto and pricing pressures. Analyst sentiment is mixed with 24% buy ratings, but institutional buying activity supports confidence in long-term growth.
RENT trades at $3.64, down 1.09% on the day, with a bullish technical signal from moving averages. The company reported Q1 2026 revenue growth of 29.2% year-over-year to $89.9 million, beating expectations, but net losses persist. Analyst sentiment is mixed with 42% buy ratings, while cash flow remains negative and debt levels are elevated.
The outlook hinges on execution under new leadership to achieve profitability. Investment opportunity lies in low valuation multiples if subscriber growth accelerates, but risks include high leverage and sustained cash burn. Wall Street consensus leans cautious despite recent earnings beats.
Trailing returns across standard periods
Latest headlines on both assets
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →Rent the Runway Inc is an e-commerce platform that allows users to rent, subscribe, or buy designer apparel and accessories.
Read more on RENT →